Lyell Immunopharma Inc.

11/05/2024 | Press release | Distributed by Public on 11/05/2024 09:04

Lyell Announces Presentation of Initial Clinical Data from the Phase 1 2 Clinical Trial of IMPT 314 for the treatment of B cell Lymphoma at the 2024 American Society of[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.